New Orleans – it’s Day 3, Monday, at the 2016 annual meeting of the American Association for Cancer Research (AACR). Attending AACR for the first time can be a daunting prospect, with a full program of activities from dawn to dusk.
For those of who don’t regularly go to large medical meetings, it’s all too easy to forget the sheer scale of the event and how mach walking is involved up and down long corridors – it’s easy to clock up 15,000+ steps on your Fitbit!
Subscribers can log-in or you can purchase a subscription by clicking on the blue box below to learn more insights…
New Orleans – here at the annual meeting of the American Association for Cancer Research (AACR), the emphasis has shifted from yesterday’s education program to the start of the scientific programme.
If you didn’t make it to the Cell Press/Nanostring, “What’s Next: Bit Topics in Cancer Immunology” event yesterday evening at the Bourbon Orleans hotel in the heart of the French Quarter, you missed a great unofficial AACR16 event that featured a panel of leading experts:
- Aviv Regev, PhD (Broad Institute of MIT and Harvard)
- Tom Gajewski, MD, PhD (University of Chicago)
- Dan Chen, MD, PhD (Genentech)
- Pam Sharma, MD, PhD (University of Texas MD Anderson Cancer Center)
- Michel Sadelain, MD, PhD (Memorial Sloan Kettering Cancer Center)
- Jerome Galon, PhD (INSERM)
- Ira Mellman, PhD (Genentech)
- Catherine Wu, MD (Dana Farber Cancer Institute)
Throughout the day, schedule permitting, we’ll be posting top-line commentary from the sessions we’ve been in.
You can also catch up with the commentary from the Day 1 Live Blog, which has several updates from yesterday (Link).
Subscribers can login below or you can purchase access by clicking on the blue icon.
New Orleans – the annual meeting of the American Association for Cancer Research (AACR) starts in earnest today with a full program of educational sessions presented by leading experts in different fields.
There’s a lot going on at AACR, with many sessions in parallel, so always remember the “law of two feet” – if the session you are in isn’t interesting, what you expected or isn’t meeting your needs – get up and go to another one!
Starting today and through Tuesday will be posting a daily blog with commentary around the sessions we attend and the people we speak to. It won’t be real-time, but to the extent possible we’ll be providing updates during the day.
It kills us to do semi-live posts from conferences, but they’re popular with subscribers, many of whom enjoy reading top-line commentary during the meeting, then our in-depth pieces later.
If you’d like to join the club of readers who enjoy access to our content, much of which by definition is exclusive – we don’t think anybody else does what we do or talks to as many thought leaders….
The good news is that a quarterly subscription will also cover you for ASCO 2016 in Chicago. If you’d like to support our conference coverage, you can purchase access below. Subscribers can login to read more.
The 2016 annual meeting of the American Association for Cancer Research (AACR) takes place next month in New Orleans. (Twitter #AACR16).
While many people have focused on the presentation of clinical data at ASCO, we have long argued that emerging scientific data at AACR actually give early hint of what’s to come down the pipeline.
Anticipating these trends and spotting promising new compounds or combinations is probably more art than science, but nonetheless is a very useful and important exercise.
AACR is the most important meeting of the year for cancer new product development!
Tomorrow, we will be reviewing the actual abstracts, posters, late breakers and what they entail, including important new data such as BMS’s CheckMate–141 exploring nivolumab in Head & Neck cancer as well as the combination of nivolumab plus ipilimumab in CheckMate–069 for advanced melanoma.
In the meantime, what are the main hot topics emerging from this year’s meeting in targeted therapies and immunotherapies? What do the key scientific sessions tell us about new directions that lie ahead?
To learn more, subscribers can sign-in below or you sign-up in the blue box.